MP Advisors Market Research Reports

TITLE Actions
Global Rising Stars Outlook 2015: Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets.
Published in Jan 2015 | US $ 2000 Onwards | By MP Advisors

Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets , approaches and biology is discovered. One field which is poised to bring a paradigm change in the way diseases are treated in the next decades is t...

Dietary Supplements: World of Opportunities In the Indian Healthcare Market
Published in Jan 2015 | US $ 2000 Onwards | By MP Advisors

Increasing rate of chronic diseases has emphasized the need of Prevention over Intervention.  These proactive health solutions include nutritional supplements which promise medical or health benefits and fall between the food and pharma chain...

New Phase of Mab biosimilar knocks the door Biosimilar Oppurtunities In Japan
Published in Jan 2015 | US $ 4000 Onwards | By MP Advisors

The launch of Remicade biosimilar in Dec-2014 in the Japan pharma market demonstrated its changing regulatory environment; it is faster than U.S. in adapting to biosimilar use. After nine years of continuous efforts by the JP government to promote...

Moderate to Severe Pain: Novel Abuse Deterrent Formulation Technologies and Emergence of Novel Mechanisms in the Management of Pain
Published in Jan 2015 | US $ 3000 Onwards | By MP Advisors

Pain is the leading cause of disability in the US, affecting more than cancer, diabetes and heart disease combined. Current analgesics for persistent pain are relatively ineffective, are associated with significant adverse effects or abuse liabili...

Therapeutic Class Overview : Psoriasis – Plaque Psoriasis & Psoriatic Arthritis : Novel Oral drugs and Biologics to Change Future Treatment Paradigm
Published in Feb 2014 | US $ 2500 Onwards | By MP Advisors

Over the last decades, therapeutic options for Plaque Psoriasis (PsO) and Psoriatic Arthritis (PsA) have expanded considerably and improved patients’ pain, function, and quality of life.  Approved biologics fill in a critical unmet need...

Innovative Drug Delivery Systems Opportunities for Generic & Specialty Pharmaceutical companies
Published in Feb 2014 | US $ 2500 Onwards | By MP Advisors

There are more than 1400 sustained or controlled release drugs have been approved all over the world. Revenues within the global generics market reached an estimated value of $265 b in 2012, showing a growth of 9.3% throughout the year. The contri...

Therapeutic Class Overview: Treating Refractory Hematological Malignancies
Published in Feb 2014 | US $ 2500 Onwards | By MP Advisors

Targeting unmet needs in the treatment of cancer/ hematological malignancies through innovative drug development strategies have witnessed favorable outcomes.  Over the past decade, Proteasome inhibitor, Velcade (bortezomib) and the immunomod...

Therapeutic Class Overview: Newer Oral Anti Androgens – Expanding Role in the treatment Paradigm of Prostate Cancer
Published in Feb 2014 | US $ 2500 Onwards | By MP Advisors

XTANDI (Enzalutamide) – Does it have potential to compete against ARN-509 in earlier setting? Zytiga (Abiraterone Acetate) – Ongoing Combination trials creates potential beyond Patent Expiry...

Therapeutic Class Overview : New Avatars Of Microbes Super Bugs A Growing Threat Worldwide
Published in Feb 2014 | US $ 1500 Onwards | By MP Advisors

Novel approaches to treat infection is growing as the need is urgent! Misuse/overuse of antibiotics accelerated antimicrobial resistance (AMR) and has resulted in the emergence of “super bugs” which are posing life threatening challeng...

Therapeutic Class Overview : Emergence Of Biogenerics Era In Japan - It's Time to Welcome Antibody Biosimilars of Foreign Origins Soon
Published in Feb 2014 | US $ 2500 Onwards | By MP Advisors

With three products and eight players already in market – Japan biosimilar market will enter new phase of biosimilars with first ‘mab’ approval expected in 2014.  This approval (Remicade- FY03/13A sales ¥73.5, infiximab ...

Regenerative Medicine and Stem cell based Cell therapies - Drugs of the Future Offering Hope for Cure
Published in Jan 2014 | US $ 3000 Onwards | By MP Advisors

Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets, approaches and biology is discovered. Improved health care, nutrition and preventive medicine in the last few decades have all helped in increasing ...

Global Pharmaceutical and Biotechnology Outlook 2014 :Rising Stars
Published in Jan 2014 | US $ 2500 Onwards | By MP Advisors

Innovations have contributed to the availability of a range of new treatments for diseases resulting in improvement in the length and quality of life and reduced disease burden for individuals and society.  However, the need for innovative th...

Global Pharmaceutical and Biotechnology Outlook 2014 - India Pharma
Published in Jan 2014 | US $ 2500 Onwards | By MP Advisors

Indian companies are taking center stage in Complex Generics at US and EU markets.  In Bio-similars, Indian companies will have perhaps the largest basket aimed at Emerging Countries in 2014-16 and later for Developed countries. Though few bu...

Global Pharmaceutical and Biotechnology Outlook 2014 - Japan Pharma
Published in Jan 2014 | US $ 2500 Onwards | By MP Advisors

2014 will be marked as a transition year for the Japanese Pharma industry - the year is bound to be painful both for innovators and generic companies due to the new regulations.  We find these regulations to be 'decisive' in spurring ...

Global Pharmaceutical & Biotechnology Outlook 2014: Major US and EU
Published in Jan 2014 | US $ 2500 Onwards | By MP Advisors

Strategy Diversification Divested: Productivity measurements, Divestment of non-core assets resulting in healthy Cash position- Will accelerate Next wave of targeted acquisitionIn the recent years several new therapies have...

Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech
Published in Jan 2014 | US $ 2500 Onwards | By MP Advisors

Positive sentiments for the biotech sector have prevailed in the last two to three years, and we expect this trend to continue for the next year too.  Our optimism is based on the continuity in the flow of innovative products from their pipel...

We are on:

Need Help?

Buy Any Report Avail 20% Discount. Coupon Code: OCT20